Author

George Duvall

Observed names: George Aaron DuVall, George Aaron Duvall

Observed institutions: Goethe University Frankfurt, Agaplesion Markus Hospital

OpenAlex ID: A5071506376

Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial

2022 · Bruce E Sands, Peter M Irving, et al. · The Lancet · 309

Risankizumab for Ulcerative Colitis

2024 · Edouard Louis, Stefan Schreiber, et al. · JAMA · 135

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

2024 · Marc Ferrante, Marc Ferrante, et al. · The Lancet · 120

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

2024 · David T Rubin, Jessica R Allegretti, et al. · The Lancet · 113

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

2023 · Laurent Peyrin-Biroulet, Jessica R. Allegretti, et al. · Gastroenterology · 104

Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

2023 · Silvio Danese, Remo Panaccione, et al. · The Lancet. Gastroenterology & hepatology · 75

Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial

2026 · Millie Long, Jessica R Allegretti, et al. · The Lancet. Gastroenterology & hepatology · 9

Efficacy and safety of duvakitug in patients with Crohn's disease (RELIEVE UCCD): a phase 2b, randomised, placebo-controlled trial

2026 · Vipul Jairath, Jaroslaw Kierkuś, et al. · The Lancet. Gastroenterology & hepatology · 8

Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial

2026 · Anita Afzali, Silvio Danese, et al. · Inflammatory Bowel Diseases · 3

130 Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT-1 and 2)

2025 · Bruce E. Sands, Silvio Danese, et al. · The American Journal of Gastroenterology · 1

S907 Guselkumab Improves Abdominal Pain and Bowel Urgency Symptoms in Patients With Moderately to Severely Active Ulcerative Colitis: Results From the Phase 3 QUASAR Induction Study

2023 · David T. Rubin, Julian Panés, et al. · The American Journal of Gastroenterology

Works count: 11

Citation count: 875

H-index: 8

I10-index: 6